HARROW INC (HROW) Stock Price, Quote, News and Overview
NASDAQ:HROW - Nasdaq - US4158581094 - Common Stock - Currency: USD
HROW Quote, Performance and Key Statistics
36.14
+1.59 (+4.6%)
The current stock price of HROW is 36.14 USD. In the past month the price increased by 18.84%. In the past year, price increased by 44.5%.
HROW Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.34 | 721.70B | ||
| JNJ | JOHNSON & JOHNSON | 16.3 | 392.14B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.89 | 290.11B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.07 | 226.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.92 | 214.74B | ||
| MRK | MERCK & CO. INC. | 10.46 | 204.70B | ||
| PFE | PFIZER INC | 7.66 | 139.75B | ||
| SNY | SANOFI-ADR | 10.79 | 118.47B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.55 | 97.81B | ||
| GSK | GSK PLC-SPON ADR | 8.25 | 73.78B | ||
| ZTS | ZOETIS INC | 24.92 | 66.79B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 64.09 | 46.04B |
Related stock screener links
About HROW
Company Profile
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The firm is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. The company provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Company Info
HARROW INC
1A Burton Hills Blvd, Suite 200
Nashville TENNESSEE 37205 US
CEO: Mark L. Baum
Employees: 382
Phone: 16157334731
HARROW INC / HROW FAQ
What is the stock price of HARROW INC today?
The current stock price of HROW is 36.14 USD. The price increased by 4.6% in the last trading session.
What is the ticker symbol for HARROW INC stock?
The exchange symbol of HARROW INC is HROW and it is listed on the Nasdaq exchange.
On which exchange is HROW stock listed?
HROW stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HARROW INC stock?
13 analysts have analysed HROW and the average price target is 56.98 USD. This implies a price increase of 57.68% is expected in the next year compared to the current price of 36.14. Check the HARROW INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HARROW INC worth?
HARROW INC (HROW) has a market capitalization of 1.33B USD. This makes HROW a Small Cap stock.
How many employees does HARROW INC have?
HARROW INC (HROW) currently has 382 employees.
Is HARROW INC (HROW) expected to grow?
The Revenue of HARROW INC (HROW) is expected to grow by 45.74% in the next year. Check the estimates tab for more information on the HROW EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HARROW INC (HROW) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HROW, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HROW, evaluating the profitability, health, valuation and growth aspects
- HARROW INC (HROW) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HARROW INC (HROW) Sales and EPS estimates to see what analysts future expectations are.
- HARROW INC (HROW) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HARROW INC (HROW) Insider and Institutional Ownership to learn about the owners and their transactions.
- HARROW INC (HROW) Stock Chart to make your own analysis
- HARROW INC (HROW) Latest news and press-releases to stay up to date.
Does HARROW INC (HROW) stock pay dividends?
HROW does not pay a dividend.
When does HARROW INC (HROW) report earnings?
HARROW INC (HROW) will report earnings on 2025-08-05, after the market close.
What is the Price/Earnings (PE) ratio of HARROW INC (HROW)?
HARROW INC (HROW) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.56).
What is the Short Interest ratio of HARROW INC (HROW) stock?
The outstanding short interest for HARROW INC (HROW) is 13.27% of its float. Check the ownership tab for more information on the HROW short interest.
HROW Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to HROW. When comparing the yearly performance of all stocks, HROW is one of the better performing stocks in the market, outperforming 90.79% of all stocks.
HROW Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to HROW. While HROW is still in line with the averages on profitability rating, there are concerns on its financial health.
HROW Financial Highlights
Over the last trailing twelve months HROW reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 37.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.96% | ||
| ROE | -38.43% | ||
| Debt/Equity | 1.99 |
HROW Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to HROW. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 151.04% and a revenue growth 45.74% for HROW